TB-500 has no clinical dose. The 2 to 2.5 mg twice-weekly schedule that fills the internet traces back to no trial, and the thymosin beta-4 that was actually given to people used different amounts, different routes and a different molecule. This guide lays every figure side by side and shows where each one comes from.
Quick answer: There is no approved or clinically tested TB-500 dose. FDA’s May 2026 review found no article in which TB-500 was given to a human.[1] The human amounts that do exist belong to full-length thymosin beta-4: intravenous doses of 42 to 1,260 mg per day for 14 days in one phase 1 trial,[13] 0.05 to 25 µg/kg in another,[15] plus eye drops and skin gels. The schedule people repeat online is 2 to 2.5 mg under the skin twice a week for 4 to 6 weeks, then 2 mg weekly. None of the pages repeating it cites a trial.[39][40][42][44] The only animal dose documented in a paper is a single 10 mg injection in horses.[3] These are reported figures, not recommendations.
Figures on this page summarize amounts and schedules reported in published research, registered trials, regulatory documents, or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported amount at a glance
Read the table in three groups. The first is TB-500 itself in people, which is empty. The second is full-length thymosin beta-4 (Tβ4) and its drug versions, which have real trials but do not describe TB-500 doses. The third is what sellers, clinics and community pages report for TB-500. Units are exactly as each source prints them. Nothing here has been converted between milligrams, micrograms per kilogram or percent strength.
Swipe the table sideways to see every column.
| Source | Substance | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|---|
| A. TB-500 (Ac-LKKTETQ) in humans | |||||||
| Published human trials | TB-500 | Humans | Not applicable | None published | Not applicable | Not applicable | No published human trial found by FDA[1] |
| Registry record NCT07487363 | TB-500 “17 to 23 fragment” | Adults with stable heart disease (planned 80) | Not stated | Dose levels “not provided” | Clinic visits | 8 weeks dosing | Record calls itself a fictional example; not evidence[33] |
| B. Human trials of full-length thymosin beta-4 and its drug versions (not TB-500) | |||||||
| RGN-352 phase 1 | Synthetic Tβ4 | Healthy adults, 4 cohorts of 10 | Intravenous | 42, 140, 420, 1260 mg per dose (units as printed) | Single dose, then the same dose daily | 14 days | Published human clinical trial (Tier 1)[13][14] |
| NL005 phase 1 | Recombinant human Tβ4 | Healthy Chinese adults, 54 single-dose and 30 multiple-dose | Intravenous | Single: 0.05, 0.25, 0.5, 2.0, 5.0, 12.5, 25.0 µg/kg. Multiple: 0.5, 2.0, 5.0 µg/kg | Single dose; multiple doses once daily | Multiple doses 10 days; 28 days of follow-up | Published human clinical trial (Tier 1)[15] |
| NL005 phase 2a, heart attack | Recombinant human Tβ4 | 62 enrolled, heart attack (STEMI) treated with PCI | Intravenous | 0.25, 0.5, 2.0 µg/kg | Once daily on days 2 to 7 after PCI, with early post-PCI doses | Observed 90 days | Registered human trial, no results posted (Tier 2)[16] |
| NL005 phase 2b, heart attack | Recombinant human Tβ4 | 90 participants | Intravenous | 0.5 and 1.0 µg/kg | Within 12 hours and on days 2 to 7 after PCI | Observed 90 days | Registered human trial, no results posted (Tier 2)[17] |
| RGN-352 phase 2, heart attack | Injectable Tβ4 | 0 enrolled | Not stated | No data | Not applicable | Not applicable | Registry record withdrawn[18] |
| Venous stasis ulcers | Tβ4 gel | 72 randomized (73 per the paper) | Topical | 0.01%, 0.03%, 0.1% (sponsor release) | Once daily | Up to 84 days | Published human clinical trial (Tier 1); strengths from sponsor release[19][20][22] |
| Pressure ulcers | Tβ4 gel | 72 across US sites | Topical | 0.01%, 0.02%, 0.1% (sponsor release) | Once daily | Up to 84 days | Registered trial, sponsor-reported results (Tier 2)[21][23][24] |
| Severe dry eye | RGN-259 eye drops | 9 patients | Eye drops | 0.1% | Six times daily | 28 days | Published human clinical trial (Tier 1)[25] |
| Dry eye, challenge chamber | RGN-259 eye drops | 72 adults | Eye drops | 0.1% | Not stated in the abstract | 28 days | Published human clinical trial (Tier 1)[26] |
| ARISE-3, dry eye | RGN-259 eye drops | 700 adults | Eye drops | Strength not stated in sources read | Four times a day | 14 days | Registered trial, sponsor-reported; missed primary endpoints[27][28] |
| SEER-1, neurotrophic keratopathy | RGN-259 eye drops | 18 patients (10 drug, 8 placebo) | Eye drops, 1 to 2 drops | 0.1% | Five times a day | 28 days | Published human clinical trial (Tier 1)[29][30] |
| SEER-2 and RGN-137 gel trials | RGN-259 drops; RGN-137 gel | 70 planned; 4 enrolled (terminated) | Eye drops; topical | 0.1% drops; gel strength not stated | Not stated | Not stated | Registered human trials (Tier 2)[31][32] |
| C. Amounts reported online for TB-500 (not clinical evidence) | |||||||
| Loading phase, most repeated | “TB-500” | Self-directed adults | Subcutaneous (intramuscular sometimes mentioned) | 2 to 2.5 mg per injection (4 to 5 mg a week) | Twice weekly | 4 to 6 weeks | Community, vendor and clinic reported (Tier 6); origin unclear[39][40][42][44][45] |
| Maintenance | “TB-500” | Self-directed adults | Subcutaneous | 2 to 2.5 mg (one source: 2 mg every 2 weeks) | Once weekly | 4 to 12 weeks | Community, vendor and clinic reported (Tier 6)[40][42][44] |
| Higher loading | “TB-500” | Self-directed adults | Subcutaneous | Up to 5 mg per injection; one source lists 2.5 mg three times weekly | Twice or three times weekly | 4 to 6 weeks | Community and physician-labeled site (Tier 5 to 6)[41][44][46] |
| Weight-based version | “TB-500” | Self-directed adults | Subcutaneous | 0.03 to 0.05 mg/kg | Twice weekly (loading) | Not stated | Vendor reported (Tier 6)[42] |
| Cycle length and breaks | “TB-500” | Self-directed adults | Not applicable | Not applicable | Not applicable | 4 to 12 weeks on, 2 to 8 weeks off; one source says maximum 90 days | Community, vendor and clinic reported (Tier 6)[39][40][41][43] |
| Horse example | “TB-500” | One horse | Subcutaneous | 2.0 to 2.5 mg, then 2.0 mg | Twice weekly, then weekly | 4 to 6 weeks, then 6 to 12 weeks | Seller page citing “some sources” (Tier 6); origin unclear[48] |
Group B amounts are not interchangeable with group C amounts. They involve a different molecule (43 amino acids versus 7), different routes, and in the intravenous trials a different way of dosing (per kilogram, or very large fixed amounts). Registry enrollment numbers are planned or registered counts. The NL005 and SEER-2 records were read as they stood on the registry on 2 November 2026.
Where these figures come from
What TB-500 is, and where sources disagree
Thymosin beta-4 (Tβ4) is a 43-amino-acid protein the body makes naturally. Its first residue, serine, already carries an acetyl cap.[11] TB-500 is the name that stuck to a much shorter piece of it. Residues 17 to 23 read LKKTETQ, and that stretch is where Tβ4 grabs actin, the protein that builds a cell’s internal scaffolding.
In 2012 a doping-control laboratory at Ghent University analyzed TB-500 packages that Belgian customs had seized. The active content was that seven-residue piece with an acetyl cap on its front end, written Ac-LKKTETQ, and the team confirmed it by building the peptide from scratch.[2][52] A Hong Kong Jockey Club laboratory reached the same identification that year and described TB-500 as a veterinary preparation whose key ingredient is acetylated LKKTETQ.[3] FDA’s 2026 review and the HHS policy both define TB-500 the same way.[1][4] The research entries for TB-500 and thymosin beta-4 keep the two apart, and the table below shows why.
Swipe the table sideways to see every column.
| Property | Full-length thymosin beta-4 | TB-500, free base | TB-500 acetate (salt form) |
|---|---|---|---|
| Length | 43 amino acids | 7 amino acids (residues 17 to 23) | 7 amino acids |
| Sequence | SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, first residue acetylated[11] | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH[1] | Same peptide with acetic acid[4] |
| Formula | C212H350N56O78S[11] | C38H68N10O14[1] | C38H68N10O14 with CH3COOH[4] |
| Mass | 4963.51[11] | 889.01 g/mol[1] | 949.1 g/mol[4] |
| CAS number | 77591-33-4[11] | 885340-08-9[1] | None listed by FDA; some sites reuse the free-base number[1] |
| Other identifiers | Not checked here | UNII QHK6Z47GTG;[1] PubChem CID 62707662 (per a reference encyclopedia)[12] | None listed |
Mass for the full-length protein is a supplier specification for the standard reference peptide, cited for identity only. The mass is in daltons, the same scale as g/mol.
Here is what can and cannot be settled.
- Settled: the name TB-500 refers to Ac-LKKTETQ in the doping-science literature and in the 2026 US regulatory documents. It is not full-length Tβ4, and FDA says so in terms: TB-500 is a common name rather than an official US drug name, and Tβ4 and TB-500 are not the same substance.[1]
- Not settled, 1: what any given vial sold under the name contains. FDA’s reviewers noted that public certificates of analysis for TB-500 skip impurity, aggregate and endotoxin testing, and that the acetate certificate submitted with the nomination reported no identification result. The nominator’s own CAS number (476014-70-7) and formula (C38H66N10O14) matched neither form.[1]
- Not settled, 2: independent testing. A third-party testing aggregator lists 174 TB-500 samples tested between 16 May 2025 and 1 July 2026, with a “Variant” column that carries both “Thymosin Beta-4” and “Fragment 17-23” labels under the one product name. It publishes no identity results.[38] A clinic-run guide warns that gray-market labeling is inconsistent and that products sold as TB-500 may be full-length protein or other fragments.[54]
- Not settled, 3: the phrase “acetylated variant.” Native Tβ4 is itself N-terminally acetylated,[11] so “acetylated thymosin beta-4” can describe the normal full-length protein as easily as the capped fragment.
- Patents: a US patent from the thymosin beta-4 wound-healing program (8,143,218) describes the shorter motif LKKTET as sequence 1 and never uses the name TB-500.[53] The name did not come from that patent text.
The most-reported figure and its origin
- Most-reported figure: 2 to 2.5 mg per injection, twice a week, for 4 to 6 weeks, then 2 mg once a week. At least six pages state it in nearly identical words.[39][40][42][44][45][48]
- Origin: not found. One reference site says the two-phase pattern “originates from” veterinary use and that the 2 to 2.5 mg range is what the research-peptide community “converged on” through self-experimentation, with no document behind either statement.[44] The only horse figure in a published paper is a single 10 mg subcutaneous dose, given for doping-control testing.[3] A seller’s horse page that lists 2.0 to 2.5 mg twice weekly attributes it to “some sources” and says no accepted equine dose exists.[48] That makes the equine page a copy of the human schedule.
- Human evidence: none for TB-500. The human amounts on this page belong to full-length Tβ4.[1]
- Animal evidence: a handful of amounts, listed in the animal section below. None leads to a human amount.
- Practitioner and community figures: documented in the community section. The sites that publish them describe their own figures as community-derived and not validated by a human trial.[40][41][42]
- Websites repeating each other: yes. Agreement among these pages reflects copying, so the figure is counted once here.
- Weight-based conversions: one vendor page gives 0.03 to 0.05 mg/kg twice weekly for loading.[42] It cites no source for that number. Everywhere else the amounts are fixed milligrams.
Detailed human data
Intravenous full-length thymosin beta-4
The two phase 1 trials are the only ones that gave Tβ4 systemically to healthy people, and both used the intravenous route. Neither involved the TB-500 fragment, and neither tested the subcutaneous route that community protocols use.
The first, run for the developer RegeneRx, gave four cohorts of 10 healthy adults a single intravenous dose of placebo or synthetic Tβ4 at 42, 140, 420 or 1260 mg, then repeated the same dose daily for 14 days. Side effects were infrequent and mild or moderate, there was no dose-limiting toxicity, drug levels rose in proportion to dose, and the half-life lengthened as the dose rose.[13] The unit is “mg” in both the abstract and the registry record, so it is reproduced as printed. The registry entry for this trial is marked withdrawn with zero enrollment even though the paper reports the cohorts, so the paper is the source to trust.[14]
The second, run by Beijing Northland Biotech with recombinant human Tβ4 (NL005), dosed by body weight. Seven single-dose cohorts (54 people) received 0.05 to 25.0 µg/kg, and three multiple-dose cohorts (30 people) received 0.5, 2.0 or 5.0 µg/kg once daily for 10 days. Side effects were mild to moderate, there were no dose-limiting toxicities or serious adverse events, and the drug did not build up with repeat dosing.[15] The sponsor moved this drug into heart-attack trials (patients treated with PCI, the procedure that reopens the blocked artery) at 0.25 to 2.0 µg/kg, but no results from those trials are posted.[16][17]
Skin gels
RegeneRx tested Tβ4 gel once daily for up to 84 days in two phase 2 trials of 72 patients each. In venous leg ulcers the 0.03% middle strength was the best performer: complete healing reached 33% versus 24% on placebo, 16% on the low strength and 17% on the high strength, and none of the differences reached statistical significance.[22] The published paper said the 0.03% strength “may have the potential” to speed healing and that about 25% of patients healed completely within three months.[19] In pressure ulcers the sponsor reported no statistically significant difference for complete healing or healing rate at any strength.[23] A later review by trial investigators said the gel accelerated healing “by almost a month” in patients who did heal.[24] The two sponsor releases list slightly different strengths (0.03% in one, 0.02% in the other), which is why both are shown above as printed.
Eye drops
The ophthalmic version, RGN-259 at 0.1%, has the largest human program. In 9 patients with severe dry eye, dosing six times a day for 28 days reduced ocular discomfort by 35.1% and total corneal staining by 59.1% compared with vehicle at day 56.[25] A 72-person trial missed both primary endpoints but showed secondary gains.[26] The 700-person ARISE-3 trial, dosed four times a day for 14 days, did not meet its primary outcome of reducing corneal staining and did not relieve ocular discomfort, according to the sponsor.[28] In neurotrophic keratopathy, a rare corneal nerve disease, SEER-1 dosed five times daily for 28 days and found complete healing in 6 of 10 treated patients versus 1 of 8 on placebo (p = 0.0656, short of the usual 0.05 bar), with no significant adverse effects.[29][30] A second trial, SEER-2, listed a primary completion date of 30 April 2026 on the registry.[31]
What the dose response says
Almost nothing carries over to TB-500. Drops that sit on the eye surface, gel on a wound and a vein infusion do not behave like an injection under the skin. The intravenous work shows that Tβ4 itself is tolerated across a very wide range of intravenous amounts, which says nothing about a seven-residue fragment given another way. The skin-gel results hint at a middle strength working best, but those differences were not statistically significant, so they cannot be read as a sweet spot.
Animal research amounts
Amounts are shown in the units each source uses. None of them can be turned into a human amount by arithmetic, and this page does not try.
Swipe the table sideways to see every column.
| Objective | Model | Substance | Amount | Route | Result or note | Evidence category |
|---|---|---|---|---|---|---|
| Doping-control kinetics | Thoroughbred geldings | TB-500 (Ac-LKKTETQ) | 10 mg, single dose | Subcutaneous | Plasma peaked at 0.05 and 0.08 ng/mL at 60 to 120 minutes and was unquantifiable by 6 to 10 hours | Published animal research (Tier 3)[3][1] |
| Metabolism | 6-week-old male rats | TB-500 | 50 mg/kg | Intraperitoneal | Acetylated breakdown products found in urine; one metabolite, Ac-LK, was highest in the first 6 hours | Published animal research (Tier 3)[35][1] |
| Wound healing | 26-month-old female mice, four 3-mm punch wounds | LKKTETQ without the acetyl cap | 0.01% solution | Topical | More closure and collagen at day 7; FDA notes this does not apply directly to acetylated TB-500 | Published animal research (Tier 3)[34][1] |
| Wound healing, cell scratch assay | Fibroblasts in a dish | TB-500 and its metabolite Ac-LKKTE | 50 µg/mL for 8 hours | In vitro | TB-500 itself produced no significant closure; the metabolite had a small significant effect | Laboratory research (Tier 4)[35][1] |
| Heart attack model | Mice with a tied coronary artery | Full-length Tβ4 | Amount not extracted here | Not extracted | Early heart-cell survival and better function reported | Published animal research (Tier 3)[36] |
Two points matter more than the numbers. FDA found no in-vivo wound-healing study of acetylated TB-500 itself, and no toxicology, genotoxicity, reproductive or intramuscular kinetics data.[1] And the 2024 rat and fibroblast work suggests that any wound-healing activity may come from a breakdown product, Ac-LKKTE, rather than from TB-500 itself.[35] The popular idea that the fragment “does what Tβ4 does” rests on the unacetylated peptide in aged mice and on full-length Tβ4 in nearly everything else.
Practitioner and community-reported protocols
This is the part most visitors came for. The table reports each source’s own numbers, labeled by what kind of source it is. A seller’s article, a clinic page and an anonymous wiki all carry the same low evidence weight here, and none is a clinical dose.
Swipe the table sideways to see every column.
| Source | Source type | Loading | Maintenance | Cycle and breaks | Route and notes | What it cites |
|---|---|---|---|---|---|---|
| Research Radar newsletter, Jan 2026 | Individual newsletter; no credentials listed | 2.0 to 2.5 mg twice weekly (4 to 5 mg a week) for 4 to 6 weeks | 2 mg every 1 to 2 weeks | 4 to 8 weeks on, 2 to 4 off; “max 90 consecutive days” | Subcutaneous; intramuscular near an injury as an option | Nothing[39] |
| Peptide Dosing Protocols, TB-500 page | Reference site; founder byline; “human-researched and AI-assisted” | About 2 to 2.5 mg twice weekly, weeks 1 to 6; acute pattern of one dose every 2 to 3 days for 2 weeks | About 2 to 2.5 mg weekly from week 7 | 4 to 12 weeks on, 4 to 8 off | Subcutaneous; calls figures “community-referenced” and not validated by a human trial of the fragment | 14 references incl. the IV phase 1 trial[40] |
| Peptide Dosing Protocols, Wolverine page | Same reference site | 2.0 to 5.0 mg twice weekly | 2.0 mg, 1 to 2 times weekly | 8 or 12 weeks, 2 to 4 off | Subcutaneous; says doses are community-derived from single-compound research | Single-compound papers only[41] |
| FormBlends article | Seller of prescription TB-500 | 2 to 2.5 mg twice weekly for 4 to 6 weeks; or 1 mg twice weekly for 2 weeks, then 2 mg twice weekly | 2 mg weekly for 6 to 12 weeks | Break of 4 to 8 weeks | Subcutaneous; also 0.03 to 0.05 mg/kg twice weekly. Says dosing comes from animal work, small case series and prescriber extrapolation | Three animal or kinetics papers[42] |
| Biohack Labs help article | Vendor help page; no author | 2 mg a week for weeks 1 to 4 (text elsewhere says 1 to 2 mg) | 2 to 5 mg a week from week 5, 1 to 2 times weekly | 8 to 12 weeks, optional 16 | Subcutaneous; suggests splitting the weekly amount, for example 1 mg twice weekly | Nothing named[43] |
| PeptideWiki dosage guide | Reference site; unnamed editors | 2 mg twice weekly, 2.5 mg twice weekly, or 2.5 mg three times weekly (4 weeks), per its tiers | 2 mg weekly for 4 to 8 weeks, 2 mg every 2 weeks, or 2.5 mg weekly for 6 to 8 weeks | Not stated | Says the protocol “originates from” veterinary use and that the community “converged on” 2 to 2.5 mg | No source linked to doses[44] |
| Peptidepedia stacking page | Reference site; “Medical Advisory Board” | 2.0 to 2.5 mg twice weekly | 2.0 to 2.5 mg weekly | Not stated | Wolverine pairing with BPC-157 | Nine references, none for the dose[45] |
| DrPatTaylor.com | Site by a physician (specialty not listed); refers readers to a telehealth service | 2 to 5 mg twice weekly for 4 to 6 weeks | 2 mg once weekly | Typically 8 to 12 weeks; some 6 | Abdominal subcutaneous injection | Two BPC-157 papers only[46] |
| Perfect B Aesthetic Medicine | Clinic page by a nurse practitioner; Wolverine blend | No mg stated; dose “in units” set by the provider | One injection daily, 5 days on and 2 off (20 a month) | 1 month per cycle, up to 3 in a row, then 2 months off | Subcutaneous abdominal injection | FDA pages[47] |
One further seller page gives an equine version of the same schedule and is covered in the “Where these figures come from” section.[48] Forum and Reddit threads were not cited because those sites could not be retrieved, and unsourced farm sites were left out on purpose.
Vial and water examples, as the sources state them
There is no correct amount of water for a vial. The concentration is the vial amount divided by the water volume, and the volume you choose only changes how the same milligrams map onto syringe markings. These are the examples the sources themselves print. They are arithmetic on a chosen volume, not dosing advice, and the reconstitution calculator will check any of them. For the method, see the guides on how much water to use and mg, mcg and syringe units.
Swipe the table sideways to see every column.
| Vial | Water added | Concentration | Draw example the source prints | Source |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | Listed in a quick-reference table | [44] |
| 5 mg | 2 mL | 2.5 mg/mL | 2 mg is 80 units; 2.5 mg is 100 units on a U-100 syringe | [42][44] |
| 10 mg | 2 mL | 5 mg/mL | 2.5 mg is 50 units | [40][42] |
| 10 mg | 2.5 mL | 4 mg/mL | “1 unit = 40 mcg” | [43] |
| 10 mg | 3 mL | 3.33 mg/mL | 2.5 mg is 75 units | [40] |
| 10 mg | 4 mL | 2.5 mg/mL | Listed in a quick-reference table | [44] |
A vial’s label amount is not a guarantee of its contents. Third-party tests of TB-500 samples found quantity differing from the advertised value by as much as 100% at the 95th percentile (see the quality section).[38]

Escalation, timing, duration and routes
- Routes in human trials: intravenous for systemic Tβ4, topical gel for wounds, eye drops for the cornea.[13][15][19][25] None of the trials read for this page used subcutaneous or intramuscular dosing.
- Routes for TB-500 outside trials: subcutaneous in nearly every protocol, intramuscular sometimes. The nominated product in FDA’s review was a 3 mg/mL lyophilized powder for subcutaneous and intramuscular injection, and the HHS policy limits TB-500 acetate to those two routes.[1][4]
- Schedules in trials: intravenous daily for 10 to 14 days in healthy volunteers and on days 2 to 7 after a heart attack; gel once daily for up to 84 days; drops four to six times a day for 14 to 28 days.
- Titration: the trials escalated between groups of people, not within one person. Community pages describe a loading phase and a lower maintenance phase, and one vendor offers a 1 mg start for two weeks before 2 mg.[42] No page ties these steps to a safety or effect finding.
- Why twice weekly? No source explains it. Nothing public shows how long TB-500 lasts in a human. In horses, plasma levels after 10 mg fell below the limit of measurement within 6 to 10 hours, Blood levels are not the same as tissue effect, so that finding does not settle the question either.[1][3]
- Time of day: no source reviewed gave a time of day, and none should be inferred.
Combinations and stacks
Formally studied: none. FDA found no article in which TB-500 was given to a human, so no combination study exists either, and a community reference site says the same.[1][41] Two reports in an FDA complaint database (HFCS) from 2004 to March 2025 involved a “blended TB-500 and BPC-157” product. They carried no safety assessment.[1]
Plausible on mechanism: both peptides have wound-healing work in animals, which is the logic behind the pairing. That is a hypothesis. The BPC-157 entry has its own evidence breakdown.
Practitioner and clinic reported: a physician-labeled site pairs 250 to 500 mcg of BPC-157 daily with 2 to 5 mg of TB-500 twice weekly for 4 to 6 weeks.[46] A clinic page describes a pre-mixed Wolverine vial injected once a day, 5 days on and 2 off, for up to three monthly cycles.[47]
Community reported: the popular form is the Wolverine stack, BPC-157 at 250 to 500 mcg daily plus TB-500 at the loading schedule above.[39][45] A reference site also lists a single pre-mixed 1:1 vial at 0.5 to 2 mg total per day, which works out to a very different TB-500 amount than the twice-weekly schedule, and the two approaches are never reconciled.[41] The KLOW blend is the same three peptides as GLOW plus KPV, and its sellers state no standard amounts. A guide notes that the name is a market label and that doses, ratios and purity vary by seller.[49]
The HHS policy requires each compounded product to contain a single active ingredient from its list. A blended TB-500 and BPC-157 product is outside the conditions the policy sets.[5]
Side effects, quality and sourcing risks as reported
- Human side-effect data for TB-500: none published. FDA’s adverse-event system returned no TB-500 reports through 26 March 2025.[1] An absence of reports says little about safety.
- Tβ4 trials: adverse events were infrequent and mild to moderate with intravenous Tβ4,[13][15] and no significant adverse effects were reported in the neurotrophic keratopathy eye-drop trial.[29] These findings belong to a different molecule, route and schedule.
- Immune reaction: FDA is concerned about immunogenicity (the body making antibodies to an injected peptide), which can be amplified by clumping.[1] The NL005 trial measured anti-drug antibodies, but its abstract reports no result for them.[15]
- Theoretical tumor concern: Tβ4 promotes cell migration and blood-vessel growth, and one community wiki raises tumor promotion as a theoretical worry, with no citation, while noting no human trial has linked injected Tβ4 to cancer.[55] A mouse study found that silencing Tβ4 slowed colorectal tumor growth.[37] This is unproven in either direction for TB-500.
- Purity and amount: an independent testing aggregator reports 174 TB-500 samples from 16 May 2025 to 1 July 2026. Purity typically ranged from 85.85% to 99.91% (5th to 95th percentile), and quantity differed from the advertised amount by as much as 100% at the 95th percentile.[38] Of 16 vendors with grades listed, 3 got an A, 1 a B, 2 a C, 1 a D, 7 an E and 2 an F. The page’s headline counts (29 vendors) and table (16) do not match, so read these figures as a rough picture.[38]
- Certificates: FDA found public certificates of analysis lacking tests for impurities, aggregates and endotoxin. See the guide to reading a COA.[1]
- Sterility and handling: no TB-500 specific data. General points are in the storage guide.
Regulatory and development status
Verified against the primary FDA and HHS documents on 2 November 2026. TB-500 is not an approved drug anywhere. FDA’s briefing records that no TB-500 product is approved in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, that the EMA has authorized none, and that TB-500 is in neither the European nor the Japanese pharmacopoeia.[1] Australia treats it as a prescription-only medicine.[51] The World Anti-Doping Agency prohibits it at all times under section S2.3.[50]
Swipe the table sideways to see every column.
| Date | Event | Source |
|---|---|---|
| 2011 to 2012 | A veterinary “TB-500” preparation appears; doping labs identify its active content as Ac-LKKTETQ | [1][2][3] |
| 29 September 2023 | TB-500 placed in Category 2 of FDA’s interim list of bulk substances for compounding (Category 2 flags significant safety concerns) | [4] |
| 15 April 2026 | FDA announces a July advisory committee meeting that names TB-500 and moves to remove 12 peptides from Category 2 | [8] |
| 22 April 2026 | Category 2 status for TB-500 ends | [4] |
| 15 May 2026 | FDA briefing document proposes not adding TB-500 free base or acetate to the 503A bulks list: poorly characterized, no human data, no reported compounding, immunogenicity risk | [1] |
| 23 July 2026 | Advisory committee votes 8 to 6, one abstention, to recommend adding TB-500 for wound healing; the vote is advisory | [7][9] |
| 24 August 2026 | FDA warns five online peptide sellers that “research use only” labels do not outweigh evidence of human use, counting dosing guidance and reconstitution tools; TB-500 was not among the peptides in those letters | [10] |
| 28 to 30 October 2026 | HHS publishes an interim enforcement discretion policy naming six peptides including TB-500 acetate for subcutaneous or intramuscular injection; Federal Register notice scheduled for 30 October with comments for two weeks; the notice calls it a draft and says it binds no one | [4][5][6] |
In plain terms, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds TB-500 acetate under ten conditions, until a final rule addresses it. Those conditions include a patient-specific prescription, an FDA-registered source with a valid certificate of analysis, a single active ingredient, an FDA-cleared syringe as the only device, and a label reading “This is a compounded drug product. Not for resale.”[4][5] HHS cites a better-documented identity, documented historical compounding use and safety concerns it calls inferential, though it also records that FDA’s drug center could not identify any pharmacy compounding TB-500.[4] The policy is not an approval, not a finding of safety or effectiveness, and not a listing on the bulks list, and it does not reach products sold online as research chemicals. The HHS policy explainer and the Atlas policy tracker follow it as it changes. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy.
What is not public
- Any human pharmacokinetic data for Ac-LKKTETQ: how much reaches the blood after a subcutaneous or intramuscular dose, and how long it stays.
- Any human safety or efficacy data for TB-500, including at the 2 to 2.5 mg amount.
- The origin of the loading schedule, and whether it was ever derived from an equine product label.
- Whether sold vials are the acetylated fragment, the free base, the salt, full-length Tβ4, or a mixture.
- Results from the NL005 heart-attack trials, which would be the best newer human data on Tβ4 itself.
- Whether the Federal Register policy changes after the comment period, and whether a final rule adds TB-500 to the bulks list.
- Dose-response data for any route other than intravenous, eye, or skin.
Frequently asked questions
What is the TB-500 dosage?
There is no clinically established TB-500 dosage. The schedule most often repeated online is 2 to 2.5 mg subcutaneously twice a week for 4 to 6 weeks, then 2 mg weekly, but none of the pages that repeat it cites a trial. The human trials that exist tested full-length thymosin beta-4, not TB-500.
Is there a TB-500 dosage chart?
There is no clinical chart. Any chart that lists “units” per dose depends on an assumed vial size and water volume, and is a conversion of a community number. The tables above are the closest honest version: they show each figure with its source and evidence category.
What is a TB-500 loading phase?
It is the first stretch of a community protocol, usually 4 to 6 weeks at 2 to 2.5 mg twice a week (4 to 5 mg a week), before dropping to a weekly maintenance amount. Some pages go higher, up to 5 mg per injection or 2.5 mg three times a week. No trial supports the idea of loading.
How much water goes in a 5 mg TB-500 vial?
There is no required amount. Concentration is the vial amount divided by the water volume. The published examples use 1 mL (5 mg/mL) or 2 mL (2.5 mg/mL) for a 5 mg vial. The volume only changes syringe markings, not the milligrams in the vial. Use the reconstitution calculator to check the arithmetic.
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 is a 43-amino-acid protein the body makes. TB-500, as FDA and doping laboratories define it, is a 7-amino-acid acetylated fragment of it (residues 17 to 23). FDA states they are not the same substance. All published human trials used Tβ4 or its drug forms.
Can TB-500 and BPC-157 be used together?
No published study has tested them together, and FDA found no human administration of TB-500 at all. The combination is a community practice, usually BPC-157 at 250 to 500 mcg daily with TB-500 on the loading schedule. The HHS enforcement policy covers single-ingredient compounded products, so a blend falls outside it.
How long is a TB-500 cycle?
Pages report 4 to 12 weeks on, followed by 2 to 8 weeks off, with one stating a 90-day maximum. These are community conventions with no trial behind them.
Is TB-500 legal?
It is not FDA approved. Since 28 October 2026, HHS says it does not intend to enforce against licensed pharmacies or physicians that compound TB-500 acetate for a patient under ten conditions, but that policy is interim, non-binding, and not an approval. Online “research use only” sales are different, and FDA has warned sellers that disclaimers do not protect them. WADA bans it in sport at all times.
What are the side effects of TB-500?
No human side-effect data exist for TB-500. In trials of full-length thymosin beta-4, adverse events were mild to moderate. FDA’s concerns for injectable peptides are immune reactions and product quality. The tumor-promotion worry is theoretical.
Has TB-500 been tested in people?
FDA’s May 2026 review found no article in which it was given to a human. A registry record titled as a TB-500 trial describes itself as a fictional example, so it does not count.

Bottom line
What is genuinely published: full-length thymosin beta-4 was given intravenously at 42 to 1,260 mg a day for 14 days in one phase 1 trial,[13] at 0.05 to 25 µg/kg in another,[15] and as gels and eye drops, with modest and mixed results. What is merely reported online: 2 to 2.5 mg twice weekly for TB-500, with no traceable origin and a horse page that copies the human schedule. What is speculative: that the fragment replicates what the full protein did, that the loading phase matters, and that any regimen has a best amount. The identity question is partly closed. By the best evidence the name means Ac-LKKTETQ. What any vial contains is still unresolved. In the US the substance is unapproved, advised for the compounding list by a narrow 8 to 6 committee vote, and covered since late October by a non-binding enforcement policy, with no human data behind it.
Keep reading
Sources
- US Food and Drug Administration. Briefing document: TB-500 (free base) and TB-500 acetate, evaluation for the 503A bulks list. Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. Dated 15 May 2026. https://www.fda.gov/media/193349/download Regulator briefing document
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. doi:10.1002/dta.1402. PMID 22962027. https://doi.org/10.1002/dta.1402 Laboratory identification study (Tier 4)
- Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043. PMID 23084823. https://doi.org/10.1016/j.chroma.2012.09.043 Published animal research (Tier 3)
- US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances: Appendix B (TB-500 identity, routes, category history). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Regulator document
- US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (ten conditions; Appendix A). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf Regulator document
- Office of the Secretary, HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice FR Doc. 2026-22192, Docket HHS-OASH-2026-0496; public inspection copy, scheduled for publication 30 October 2026. https://public-inspection.federalregister.gov/2026-22192.pdf Regulator document (Federal Register)
- DLA Piper. FDA advisory committee recommends adding six peptides to the bulks list. 31 July 2026. https://www.dlapiper.com/insights/publications/2026/07/fda-adcomm-recommends-adding-six-peptides-to-bulk-list Law-firm summary (secondary)
- Goodwin. FDA signals potentially evolving stance toward compounding of certain peptides. May 2026. https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides Law-firm summary (secondary)
- WYPR (NPR member station). FDA panel considers easing peptide restrictions. 23 July 2026, updated 24 July 2026. https://www.wypr.org/2026-07-23/fda-panel-considers-easing-peptide-restrictions News report (secondary)
- AFS law firm alert. RUO-ined: five peptide vendors learn that “research use only” is not a legal strategy (FDA warning letters of 24 August 2026). https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy Law-firm summary (secondary)
- Bachem. Thymosin β4 (human, bovine, horse, rat), product specification: sequence, formula, mass, CAS 77591-33-4. https://shop.bachem.com/?p=257788 Reference peptide specification (supplier catalog; cited for sequence and mass only)
- Wikipedia. TB-500 (identifiers including PubChem CID 62707662). https://en.wikipedia.org/wiki/TB-500 Reference encyclopedia (secondary); identifiers to be confirmed in PubChem
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. doi:10.1111/j.1749-6632.2010.05474.x. PMID 20536472. https://doi.org/10.1111/j.1749-6632.2010.05474.x Published human clinical trial (Tier 1)
- ClinicalTrials.gov. NCT00743769: phase 1 intravenous thymosin beta 4 in healthy volunteers. Sponsor: RegeneRx Biopharmaceuticals. https://clinicaltrials.gov/study/NCT00743769 Trial registry record (withdrawn, 0 enrolled)
- Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. doi:10.1111/jcmm.16693. PMID 34346165. https://doi.org/10.1111/jcmm.16693 Published human clinical trial (Tier 1)
- ClinicalTrials.gov. NCT05485818: phase IIa recombinant human thymosin beta 4 in acute myocardial infarction. Sponsor: Beijing Northland Biotech. https://clinicaltrials.gov/study/NCT05485818 Trial registry record (Tier 2); no results posted
- ClinicalTrials.gov. NCT05984134: phase IIb recombinant human thymosin β4 (NL005) in acute myocardial infarction. Sponsor: Beijing Northland Biotech. https://clinicaltrials.gov/study/NCT05984134 Trial registry record (Tier 2); no results posted
- ClinicalTrials.gov. NCT01311518: RGN-352 in acute ST elevation myocardial infarction. Sponsor: RegeneRx Biopharmaceuticals. https://clinicaltrials.gov/study/NCT01311518 Trial registry record (withdrawn, 0 enrolled)
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. doi:10.1111/j.1749-6632.2010.05490.x. PMID 20536470. https://doi.org/10.1111/j.1749-6632.2010.05490.x Published human clinical trial (Tier 1)
- ClinicalTrials.gov. NCT00832091: thymosin beta 4 in venous stasis ulcers. Sponsor: RegeneRx Biopharmaceuticals. https://clinicaltrials.gov/study/NCT00832091 Trial registry record (Tier 2)
- ClinicalTrials.gov. NCT00382174: thymosin beta 4 in pressure ulcers. Sponsor: RegeneRx Biopharmaceuticals. https://clinicaltrials.gov/study/NCT00382174 Trial registry record (Tier 2)
- Fierce Biotech. RegeneRx reports phase II venous stasis trial results. 26 March 2009. https://www.fiercebiotech.com/biotech/regenerx-reports-phase-ii-venous-stasis-trial-results Sponsor release via trade press (secondary)
- Fierce Biotech. RegeneRx reports phase II pressure ulcer trial results. https://www.fiercebiotech.com/biotech/regenerx-reports-phase-ii-pressure-ulcer-trial-results Sponsor release via trade press (secondary)
- Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. doi:10.1111/j.1749-6632.2012.06717.x. PMID 23050815. https://doi.org/10.1111/j.1749-6632.2012.06717.x Review by trial investigators
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. doi:10.1097/ICO.0000000000000379. PMID 25826322. https://doi.org/10.1097/ICO.0000000000000379 Published human clinical trial (Tier 1)
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-884. doi:10.2147/OPTH.S80954. PMID 26056426. https://doi.org/10.2147/OPTH.S80954 Published human clinical trial (Tier 1)
- ClinicalTrials.gov. NCT03937882: RGN-259 ophthalmic solution for dry eye (ARISE-3). Sponsor: ReGenTree. https://clinicaltrials.gov/study/NCT03937882 Trial registry record (Tier 2)
- Clinical Trials Arena. LoA update: ReGenTree’s US approval chance for timbetasin in dry eye drops drops six points. 25 March 2021. https://www.clinicaltrialsarena.com/comment/loa-update-regentrees-us-approval-chance-for-timbetasin-in-dry-eye-drops-six-points/ Trade press reporting a company release (secondary)
- Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2023;24(1):554. doi:10.3390/ijms24010554. PMID 36613994. https://doi.org/10.3390/ijms24010554 Published human clinical trial (Tier 1); authors include sponsor staff
- ClinicalTrials.gov. NCT02600429 (SEER-1) study protocol: 0.1% RGN-259, 5 times per day for 28 days. https://cdn.clinicaltrials.gov/large-docs/29/NCT02600429/Prot_000.pdf Trial protocol document
- ClinicalTrials.gov. NCT05555589: 0.1% RGN-259 ophthalmic solution for neurotrophic keratopathy (SEER-2). Sponsor: ReGenTree. https://clinicaltrials.gov/study/NCT05555589 Trial registry record (Tier 2)
- ClinicalTrials.gov. NCT03578029: RGN-137 topical gel in epidermolysis bullosa (CELEB). Sponsor: Lenus Therapeutics. https://clinicaltrials.gov/study/NCT03578029 Trial registry record (terminated, 4 enrolled)
- ClinicalTrials.gov. NCT07487363: Phase 1/2 study of TB-500 (thymosin beta 4 17-23 fragment) in stable atherosclerotic cardiovascular disease. Sponsor: Hudson Biotech. The record’s own summary describes the study as a fictional example. https://clinicaltrials.gov/study/NCT07487363 Registry record; not valid human evidence
- Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x. PMID 12581423. https://doi.org/10.1046/j.1524-475x.2003.11105.x Published animal research (Tier 3)
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033. doi:10.1016/j.jchromb.2024.124033. PMID 38382158. https://doi.org/10.1016/j.jchromb.2024.124033 Published animal and laboratory research (Tier 3 and 4)
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000. PMID 15565145. https://doi.org/10.1038/nature03000 Published animal research (Tier 3)
- Chao TC, Chan LC, Ju SY, et al. In vivo growth suppression of CT-26 mouse colorectal cancer cells by adenovirus-expressed small hairpin RNA specifically targeting thymosin beta-4 mRNA. Cancer Gene Ther. 2014;21(9):389-396. doi:10.1038/cgt.2014.43. PMID 25124811. https://doi.org/10.1038/cgt.2014.43 Published animal research (Tier 3)
- Finnrick. TB-500 testing summary: 174 samples, 16 May 2025 to 1 July 2026 (page dated through 1 July 2026). https://demo.finnrick.com/products/tb-500 Independent testing aggregator; identity results not published
- Pruski D. The Wolverine Stack: your complete guide to BPC-157 and TB-500 for injury healing. Research Radar (Substack), 27 January 2026. https://derekpruski.substack.com/p/the-wolverine-stack-your-complete Community reported (Tier 6); no sources cited
- Peptide Dosing Protocols. TB-500 Quick Start (protocol page). https://www.peptidedosingprotocols.com/protocol/tb-500 Community reference site (Tier 6); calls figures community-referenced
- Peptide Dosing Protocols. Wolverine Stack Quick Start. https://www.peptidedosingprotocols.com/stacks/wolverine Community reference site (Tier 6)
- FormBlends. TB-500 dosage protocols. https://formblends.com/peptides/tb-500-dosage-protocols Vendor reported (Tier 6)
- Biohack Labs help center. TB-500 10mg dosage guide. https://intercom.help/bio-hack-lab-help-center/en/articles/13837336-tb-500-10mg-dosage-guide Vendor reported (Tier 6)
- PeptideWiki Editorial Team. TB-500 dosage guide: loading, maintenance and what the research shows. Published 20 February 2026. https://peptidewiki.co/guides/dosage-guides/tb-500-dosage-guide Community reference site (Tier 6); no source linked to doses
- Peptidepedia. TB-500 stacking (Wolverine stack). https://peptidepedia.org/recovery/tb-500/stacking Community reference site (Tier 6)
- DrPatTaylor.com. The Wolverine stack: BPC-157 and TB-500. https://www.drpattaylor.com/learn/wolverine-stack-bpc-157-tb-500 Practitioner-labeled site (Tier 5 to 6)
- Perfect B Aesthetic Medicine. TB-500 dosage protocol: how the 3-month cycle works. https://www.perfectb.com/?p=22855 Clinic page (Tier 5 to 6)
- First Choice Equine. What is TB-500 (thymosin beta-4 fragment) for horses? https://www.firstchoiceequine.com/post/what-is-tb-500-thymosin-beta-4-fragment-for-horses Seller page (Tier 6); attributes figures to “some sources”
- Superpower. GLOW peptide blend: GHK-Cu, BPC-157 and TB-500, and how KLOW differs. https://superpower.com/guides/peptide-science/glow-peptide Health-company guide (secondary)
- Sport Integrity Australia. Thymosin beta-4 (WADA Prohibited List section S2.3). https://www.sportintegrity.gov.au/what-we-do/anti-doping/substance-education/thymosin-beta-4 Anti-doping authority
- Healthy Male. What you need to know about the “Wolverine stack”. https://healthymale.org.au/health-article/what-you-need-to-know-about-the-wolverine-stack Health information site (secondary)
- Esposito S, et al. TB-500 identification (conference proceedings, volume 21). German Sport University Cologne (DSHS Köln). https://www.dshs-koeln.de/fileadmin/redaktion/Institute/Biochemie/PDF/Proceedings/Proceedings_21/21_p054_lecture_22_Esposito.pdf Conference abstract (Tier 4)
- US Patent 8,143,218. Treatment of skin, and wound repair, with thymosin beta 4. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8143218 Patent document
- Superpower. TB-500: a synthetic thymosin beta-4 actin-binding fragment. Published 18 April 2026. https://superpower.com/guides/peptides/tb-500 Clinic-company guide (secondary)
- Peptide Protocol Wiki. TB-500 risks. https://www.peptideprotocolwiki.com/peptides/tb500/risks Community reference site (Tier 6); no citations for tumor claim
Educational reference only, not medical advice. This page documents amounts reported in published research, registered trials, regulatory documents and online sources. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.